✦ LIBER ✦

T.P.1.01 Use of the 6 min walk test as an endpoint in clinical trials for neuromuscular diseases

✍ Scribed by J.M. Florence; A. van der Ploeg; P.R. Clemens; D.M. Escolar; P. Laforet; B. Rosenbloom; M. Wasserstein; A. Skrinar; A. Pestronk; J.E. Mayhew

Book ID: 116793471
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 62 KB
Volume: 18
Category: Article
ISSN: 0960-8966
DOI: 10.1016/j.nmd.2008.06.053

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

T.P.1.02 The 6 min walk test (6MWT)

T.P.1.02 The 6 min walk test (6MWT) as a clinical trial outcome measure in Duchenne/Becker Muscular Dystrophy (DMD/BMD)

✍ C.M. McDonald; E.K. Henricson; J.J. Han; A.R. Nicorici; R.T. Abresch; L.A. Atkin 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 49 KB

The 6-min walk test (6MW) as an efficacy

The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: Demonstration of a ceiling effect

✍ Adaani E. Frost; D. Langleben; R. Oudiz; N. Hill; E. Horn; V. McLaughlin; I.M. R 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 87 KB

T.P.1.01 Use of the 6&#xa0;min walk test as an endpoint in clinical trials for neuromuscular diseases

T.P.1.01 Use of the 6 min walk test as an endpoint in clinical trials for neuromuscular diseases